HER2 Low Advanced BC: Module

CME

Pushing the Boundaries of Unresectable or Metastatic HER2-Low Breast Cancer Treatment: New Insights and Innovations

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: January 26, 2024

Expiration: January 25, 2025

Sara M. Tolaney
Sara M. Tolaney, MD, MPH

Activity

Progress
1 2
Course Completed

Introduction

In this module, Sara M. Tolaney, MD, MPH, reviews the current treatment landscape for patients with HER2-low unresectable or metastatic breast cancer and provides clinical insights into the emerging innovative strategies under investigation for patients with HER2-low breast cancer.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

An introductory module in which Sara M. Tolaney, MD, MPH, reviews the recent changes in the classification of HER2 expression levels in breast cancer and the clinical implications of the evolving spectrum of HER2 expression in breast cancer can be found here.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with breast cancer do you provide care for in a month?

A 58-year-old woman with a history of stage II estrogen receptor–positive/HER2 immunohistochemistry (IHC) 1+ invasive ductal carcinoma was referred to your clinic. Eight years ago, she received adjuvant endocrine therapy with an aromatase inhibitor (AI) but experienced disease recurrence while receiving AI therapy. She received fulvestrant plus a CDK4/6 inhibitor for 8 months before she developed progressive disease with new liver metastases. She then received capecitabine, but she developed disease progression with worsening liver metastases. A biopsy of her liver revealed metastatic breast cancer that was estrogen receptor–positive and HER2 IHC 0.

What is the best treatment that you would recommend for this patient at this point in her care?